Company Overview and News

0
Dhanlaxmi Bank Limited - Clarification

6h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DHANBANK 532180

0
Dhanlaxmi Bank Limited - Change in Director(s)

2018-06-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DHANBANK 532180

0
Dhanlaxmi Bank Limited - Change in Director(s)

2018-06-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DHANBANK 532180

0
Dhanlaxmi Bank Limited - Interest Rates Updates

2018-06-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DHANBANK 532180

0
Dhanlaxmi Bank Limited - Change in Director(s)

2018-06-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DHANBANK 532180

0
Dhanlaxmi Bank gains 14% post company cut losses in Q4

2018-05-23 moneycontrol
Shares of Dhanlaxmi Bank advanced 14 percent intraday Wednesday as company cut its losses in the quarter ended March 2018.
DHANBANK 532180

0
Dhanlaxmi Bank Limited - Financial Result Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DHANBANK 532180

3
Jet Air, Tata Motors, IFCI results on Wednesday

2018-05-22 thehindubusinessline
About 75 companies including Aries Agro, Atlas Cycles, Bajaj Electricals, CESC, Cosmo Films, Dhanlaxmi Bank, eClerx, Entertainment Network, Eros, Finolex, GE T&D, Godrej Industries, Grasim, GVK Power, HG Infra, IFCI, Indraprastha Gas, Jet Airways, Jain Irrigation, KPIT Tech, L&T Infotech, MEP Infra, Natco Pharma, Omaxe, Ramco Cements, Repco Home, Shipping Corp, SML Isuzu, Suntech Realty, Tata Motors and Vidhi Specialty will declare their quarter and full-year results on Wednesday.
GODREJIND PQRTY 524816 532617 532935 ATLASCYCLE 532514 IGL ARIES 508814 NATCOPHARM 505029 532180 500570 500031 TATAMOTORS RMCTY 505192 JETAIRWAYS PETRONET 532700 ENIL 532522 500260 SMLISUZU RAMCOCEM DHANBANK COSMOFILMS 500164 BAJAJELEC TTM

0
Dhanlaxmi Bank Limited - Change in Director(s)

2018-05-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DHANBANK 532180

2
Focus on PNB, RCom, Syndicate Bank results

2018-05-14 thehindubusinessline
Britannia, Clariant Chemicals, CG Consumer, Dhanlaxmi Bank, Electrosteel Castings, Endurance Tech, INEOS Styrolution, JBM Auto, JHS Svendgaard, Jindal Poly, Lupin, Mangalam Cement, Monsanto, MRPL, PI Industries, Punjab National Bank, Reliance Communications, Selan Exploration, Snowman Logistics, Suven Life Sciences, Syndicate Bank and Texmaco Infra are among the 35 companies that will declare their results for Q4 and FY18 on Tuesday.
500128 506390 532605 530239 532712 JBMA 538635 SUVEN SYNDIBANK ELECTCAST 532276 PNJZY RCOM MANGLMCEM 532461 DHANBANK CLNINDIA PNB 532180 SNOWMAN 502157

0
Dhanlaxmi Bank Limited - Interest Rates Updates

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
DHANBANK 532180

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...